Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules

Journal of the American Pharmacists Association

Volumn 47, Issue 6, 2007, Pages 747-755

  Winiarski, Aleksander P ^a   Infeld, Martin H ^a   Tscherne, Ronald ^a   Bachynsky, Maria ^a   Rucki, Richard ^a   Nagano Mate, Kathy ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

Compounding (extemporaneous); Influenza (avian); Oseltamivir; Stability

Indexed keywords

ANTIVIRUS AGENT; DRUG VEHICLE; OSELTAMIVIR;

ARTICLE; BACTERIAL COUNT; CHEMISTRY; DRUG CONTAMINATION; DRUG FORMULATION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MICROCAPSULE; ORAL DRUG ADMINISTRATION; SOLUTION AND SOLUBILITY; VEHICLES;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONY COUNT, MICROBIAL; DRUG COMPOUNDING; DRUG CONTAMINATION; DRUG STABILITY; OSELTAMIVIR; SOLUTIONS; VEHICLES;

EID: 38449115489     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2007.06125     Document Type: Article

References (11)

1. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999;341:1336-43.
2. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA. 2000;283:1016-24.
3. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127-33.
4. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet. 2000;355:1845-50.
5. Aoki FY, Macleod MD, Paggioro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother. 2003;51:123-9.
6. Alymova IV, Taylor G, Portner A. Neuraminidase inhibitors as antiviral agents. Curr Drug Targets Infect Disord. 2005;5:401-9.
7. Ohuchi M, Asaoka N, Sakai T, et al. Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect. 2006;8:1287-93.
8. Tamiflu [package insert]. Nutley, N.J.: Roche Pharmaceuticals; 2005. Accessed at www.rocheusa.com/products/tamiflu/pi.pdf, May 12, 2006.
9. Channer KS, Virjee JP. The effect of formulation on oesophageal transit. J Pharm Pharmacol. 1985;37:126-9.
10. Conroy S. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals. Acta Paediatr. 2003;92:408-10.
11. Beadling C, Slifka MK. How do viral infections predispose patients to bacterial infections? Curr Opin Infect Dis. 2004;17:185-91.